You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Boehringer Ingelheim
Johnson and Johnson
Baxter
McKesson

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

Litigation Details for ALLERGAN, INC. v. SANDOZ, INC. (M.D.N.C. 2011)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

ALLERGAN, INC. v. SANDOZ, INC. (M.D.N.C. 2011)

Docket   Start Trial Date Filed 2011-04-15
Court District Court, M.D. North Carolina Date Terminated 2013-01-25
Cause 15:1126 Patent Infringement Assigned To Catherine Caldwell Eagles
Jury Demand Both Referred To L. Patrick Auld
Parties ALLERGAN, INC.; DUKE UNIVERSITY; SANDOZ, INC.
Patents 5,688,819; 6,403,649; 7,351,404; 7,388,029
Attorneys ALLEN ROBERT BAUM; BRANDON C. HELMS; BRYAN G. SCOTT; DAVID MATTHEW WILKERSON; DEANNA J. REICHEL; DOUGLAS E. MCCANN; ELIZABETH M. FLANAGAN; F. HILL ALLEN , IV; JEFFREY T. THOMAS; JENNIFER HALL; JONATHAN E. SINGER; JUANITA R. BROOKS; MEREDITH MARTIN ADDY; RASHAD L. MORGAN; ROBERT M. OAKES; ROGER A. DENNING; THOMAS J. FILARSKI
Link to Docket External link to docket
Small Molecule Drugs cited in ALLERGAN, INC. v. SANDOZ, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for ALLERGAN, INC. v. SANDOZ, INC. (M.D.N.C. 2011)

Date Filed Document No. Description Snippet Link To Document
2014-06-10 105 b. ’819 Patent U.S. Patent No. 5,688,819 (“’819 patent”) emerged from …claims of U.S. Patent Nos. 7,388,029 (“’029 patent”) and 7,351,404 (“’404 patent”) and had …The work that led to the ’029 patent, the first of the two patents asserted by appellees in this… of the ’029 patent was assigned to Duke University, and the patent issued on June 17, 2008… The second patent asserted by appellees in this suit is the ’404 patent, which is assigned External link to document
2011-08-02 26 Motion to Consolidate Cases of U.S. Patent Nos. 7,351,404 (“the ‘404 patent”), 7,388,029 (“the ‘029 patent”), and 6,403,649 (“the …of U.S. Patent Nos. 7,351,404 (“the ‘404 patent”), 7,388,029 (“the ‘029 patent”), and 6,403,649 (“the …infringement and validity of the ‘404 patent, the ‘029 patent, and the ‘649 patent. 5. The parties…the ‘649 patent”) under U.S.C. § 271(e)(2) arising from Apotex’s Abbreviated New Drug Application (“ANDA…Latisse®, prior to expiration of the ‘404 and ‘029 patents based on claims of invalidity and noninfringement External link to document
2011-10-21 39 Stipulation Plaintiffs' Count III with Respect to U.S. Patent No. 6,403,649 by ALLERGAN, INC., DUKE UNIVERSITY. Associated…2011 25 January 2013 1:11-cv-00298 830 Patent Both District Court, M.D. North External link to document
2011-10-21 40 Stipulation Plaintiffs' Count III with Respect to U.S. Patent No. 6,403,649 by ALLERGAN, INC., DUKE UNIVERSITY. Associated…2011 25 January 2013 1:11-cv-00298 830 Patent Both District Court, M.D. North External link to document
2012-04-20 57 Statement Claim Construction Statement Regarding U.S. Patent Nos. 7,351,404 and 7,388,029 Under Local Rule 104.3 by …2011 25 January 2013 1:11-cv-00298 830 Patent Both District Court, M.D. North External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Colorcon
Boehringer Ingelheim
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.